{"success":true,"data":{"pressRelease":{"id":"113904","rtpr_id":"nGNX5klZrv","ticker":"ALVO","exchange":"NASDAQ","all_tickers":["ALVO"],"title":"Alvotech to Report Financial Results for H1 2026","author":"Globe Newswire","published_at":"2026-08-10T12:00:00.732Z","article_body":"REYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO;\nALVO-SDB) (the “Company”), a global biotechnology company specializing in\nthe development and manufacture of biosimilar medicines for patients\nworldwide, today announced that it will release its financial results for the\nfirst half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.\n\nThe Company will also host a webcast with a live Q&A on Thursday, August 20,\n2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).\n* To listen to the webcast, please register here: H1 2026 webcast\n(https://edge.media-server.com/mmc/p/2qwpypd4)\n* To participate in the Q&A, please register here: Q&A registration\n(https://register-conf.media-server.com/register/BI179b5ef63d8c4924a2076cb25acf4b15)\nSlides and other material will be made available on alvotech.com/financials\n(https://www.globenewswire.com/Tracker?data=K4ictHdI1IEna7pP1QUlMRzWNiJlnIKUyubYl9cGx9-tM8nO8YmbSfHj-IN9N1ceZkChiLwUxsLnAuUi0pmv8SMZ42rNK5oj_mS-f_TKLZsomIyiUW-ny3pneS3ACHZY)\nbefore the call.\n\nFor further information, contact:\n\nMedia\nBenedikt Stefansson\nSarah MacLeod\nalvotech.media@alvotech.com\n\nInvestors\nDr. Balaji V Prasad (US)\nBenedikt Stefansson (IS)\nalvotech.ir@alvotech.com\n\nAbout Alvotech\nAlvotech is a biotechnology company, founded by Robert Wessman, focused solely\non the development and manufacture of biosimilar medicines for patients\nworldwide. Alvotech seeks to be a global leader in the biosimilar space by\ndelivering high-quality, cost-effective products and services, enabled by a\nfully integrated approach and broad in-house capabilities. Five biosimilars\nare already approved and marketed in multiple global markets, including\nbiosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi®\n(golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The\ncurrent development pipeline includes disclosed biosimilar candidates aimed at\ntreating autoimmune disorders, eye disorders, osteoporosis, respiratory\ndisease, and cancer. Alvotech has formed a network of strategic commercial\npartnerships to provide global reach and leverage local expertise in markets\nthat include the United States, Europe, Japan, China and other Asian\ncountries, and large parts of South America, Africa and the Middle East. For\nmore information, please visit https://www.alvotech.com.\n\nFor more information, please visit our website\n(https://www.globenewswire.com/Tracker?data=H0gdJgFTvS8S6qJnFtJyVl_aiEznTyO3MnOjWuJKGL5H_ZSprUiW3yoJd8JQs58KfY6dBxyTA63A5hp5n9HyvQ==)\nor follow us on social media on LinkedIn\n(https://www.globenewswire.com/Tracker?data=xRbnU6XBAq14Rko9CRPpNE6uUXcodgvCJ5pjhGXITQ4MU7a1Ve8hGkSBYA6ir4tM2lEWKc5smsnCz_7c4Ph3R74XEDsxB7dWt-sqWouERVw=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=NDLf3NluwlMrUQjTQTM20quT1cboPqRLtQYRjRadIWi72bAn5M7X8uTJ7uBrSXt1oIe5hRzM2I1nYbfMtxO7FozfYoNctw6Z-zw8xHUmC4E=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=iy9pkBuG_JLHBcEOObHnx2hUru2lKNw59WL2L-QR4hupRw6otMZCsbKcijn8LIXES1Hu_ofdrgKbWJ0ImeNpWs4LLOGBiQ9WkzsMVFboyYI=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=GU1xSKSFysVfZ0UuxTnGlOBPtbuyknaMSZ5kTIfd537z17WOCwbQH4eqn9Y306zfJaMcaJdM5J1tBTNqGrL3dG89vZGep4yxuma7W0bw0L0=).\n\nNone of the information on the Alvotech website shall be deemed part of this\npress release.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/17a8091d-68a6-47c1-968e-fcced99f1d44)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5klZrv","title":"Alvotech to Report Financial Results for H1 2026","author":"Globe Newswire","ticker":"ALVO","created":"2026-08-10T12:00:00.732Z","tickers":["ALVO"],"exchange":"NASDAQ","article_body":"REYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO;\nALVO-SDB) (the “Company”), a global biotechnology company specializing in\nthe development and manufacture of biosimilar medicines for patients\nworldwide, today announced that it will release its financial results for the\nfirst half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.\n\nThe Company will also host a webcast with a live Q&A on Thursday, August 20,\n2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).\n* To listen to the webcast, please register here: H1 2026 webcast\n(https://edge.media-server.com/mmc/p/2qwpypd4)\n* To participate in the Q&A, please register here: Q&A registration\n(https://register-conf.media-server.com/register/BI179b5ef63d8c4924a2076cb25acf4b15)\nSlides and other material will be made available on alvotech.com/financials\n(https://www.globenewswire.com/Tracker?data=K4ictHdI1IEna7pP1QUlMRzWNiJlnIKUyubYl9cGx9-tM8nO8YmbSfHj-IN9N1ceZkChiLwUxsLnAuUi0pmv8SMZ42rNK5oj_mS-f_TKLZsomIyiUW-ny3pneS3ACHZY)\nbefore the call.\n\nFor further information, contact:\n\nMedia\nBenedikt Stefansson\nSarah MacLeod\nalvotech.media@alvotech.com\n\nInvestors\nDr. Balaji V Prasad (US)\nBenedikt Stefansson (IS)\nalvotech.ir@alvotech.com\n\nAbout Alvotech\nAlvotech is a biotechnology company, founded by Robert Wessman, focused solely\non the development and manufacture of biosimilar medicines for patients\nworldwide. Alvotech seeks to be a global leader in the biosimilar space by\ndelivering high-quality, cost-effective products and services, enabled by a\nfully integrated approach and broad in-house capabilities. Five biosimilars\nare already approved and marketed in multiple global markets, including\nbiosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi®\n(golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The\ncurrent development pipeline includes disclosed biosimilar candidates aimed at\ntreating autoimmune disorders, eye disorders, osteoporosis, respiratory\ndisease, and cancer. Alvotech has formed a network of strategic commercial\npartnerships to provide global reach and leverage local expertise in markets\nthat include the United States, Europe, Japan, China and other Asian\ncountries, and large parts of South America, Africa and the Middle East. For\nmore information, please visit https://www.alvotech.com.\n\nFor more information, please visit our website\n(https://www.globenewswire.com/Tracker?data=H0gdJgFTvS8S6qJnFtJyVl_aiEznTyO3MnOjWuJKGL5H_ZSprUiW3yoJd8JQs58KfY6dBxyTA63A5hp5n9HyvQ==)\nor follow us on social media on LinkedIn\n(https://www.globenewswire.com/Tracker?data=xRbnU6XBAq14Rko9CRPpNE6uUXcodgvCJ5pjhGXITQ4MU7a1Ve8hGkSBYA6ir4tM2lEWKc5smsnCz_7c4Ph3R74XEDsxB7dWt-sqWouERVw=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=NDLf3NluwlMrUQjTQTM20quT1cboPqRLtQYRjRadIWi72bAn5M7X8uTJ7uBrSXt1oIe5hRzM2I1nYbfMtxO7FozfYoNctw6Z-zw8xHUmC4E=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=iy9pkBuG_JLHBcEOObHnx2hUru2lKNw59WL2L-QR4hupRw6otMZCsbKcijn8LIXES1Hu_ofdrgKbWJ0ImeNpWs4LLOGBiQ9WkzsMVFboyYI=)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=GU1xSKSFysVfZ0UuxTnGlOBPtbuyknaMSZ5kTIfd537z17WOCwbQH4eqn9Y306zfJaMcaJdM5J1tBTNqGrL3dG89vZGep4yxuma7W0bw0L0=).\n\nNone of the information on the Alvotech website shall be deemed part of this\npress release.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/17a8091d-68a6-47c1-968e-fcced99f1d44)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-10T12:00:00.824476037Z","server_sent_at_ms":1786363200824},"received_at":"2026-08-10T12:00:00.880Z","source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341759/0/en/alvotech-to-report-financial-results-for-h1-2026.html"},"analysis":{"id":"102905","press_release_id":"113904","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Alvotech announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.\n\nThe company will also host a webcast and live Q&A session on Thursday, August 20, 2026, at 08:00 ET.\n\nPresentation slides and additional materials will be made available on the company's investor relations website prior to the call.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine earnings calendar update."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Robert Wessman","role":"Founder"},{"name":"Dr. Balaji V Prasad","role":"Investor Relations"}],"products":["Humira®","Stelara®","Simponi®","Eylea®","Prolia®","Xgeva®"],"companies":[{"name":"Alvotech","ticker":"ALVO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine announcement of the date for an upcoming earnings release and conference call. No financial results, guidance, or material business updates were disclosed."},"tickerRelevance":{"others":[],"primary":"ALVO"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-calendar"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Alvotech announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close.\n\nThe company will also host a webcast and live Q&A session on Thursday, August 20, 2026, at 08:00 ET.\n\nPresentation slides and additional materials will be made available on the company's investor relations website prior to the call.","key_figures":null,"named_entities":{"people":[{"name":"Robert Wessman","role":"Founder"},{"name":"Dr. Balaji V Prasad","role":"Investor Relations"}],"products":["Humira®","Stelara®","Simponi®","Eylea®","Prolia®","Xgeva®"],"companies":[{"name":"Alvotech","ticker":"ALVO"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T15:09:13.139Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-calendar"}},"durationMs":394932,"modelName":"glm-4.7"}}